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Multi-drug resistance can be induced by various environmental stresses including an exposure to chemical drugs and X-ray
irradiation. In addition, hypo-nutritive conditions are known to promote multi-drug resistance in solid tumours. To understand
the importance of nutritive conditions in the development of drug resistance in non-solid tumours and to know whether a
transient malnutrition could induce a permanent reduction in drug sensitivity, leukaemic cells were transiently cultured under
growth factor-starved conditions. Granulocyte-macrophage colony-stimulating factor-dependent human leukaemic MO7e cells
were cultured in the absence of granulocyte-macrophage colon-stimulating factor for 2 weeks, during which the majority of
the cells died, and the minor viable cells were expanded in the presence of granulocyte-macrophage colon-stimulating factor
for following 1 week. This procedure was repeated three times, and the surviving cells were cloned by limiting dilution. These
clones underwent G1 arrest in the absence of granulocyte-macrophage colon-stimulating factor, while parental cells underwent
apoptosis. Interestingly, activities of the downstream targets of granulocyte-macrophage colon-stimulating factor receptor were
regulated in a granulocyte-macrophage colon-stimulating factor-independent manner, indicating that the ligand-independent
activation of granulocyte-macrophage colon-stimulating factor receptor had not taken place. Moreover, the 4–7-fold increases
in IC50 for etoposide and the 2–6-fold increase in IC90 for doxorubicin was observed. Furthermore, Bcl-2 protein expression
was signiﬁcantly up-regulated in the clones while no signiﬁcant changes in Bax, Bcl-xL, P-glycoprotein and Hsp70 protein
expression and no consistent changes in p53 expression were detected. We propose that recurrent growth factor starvation,
which may occur in vivo when stromal function is damaged after intensive chemotherapy or bone marrow occupation by
malignant cells, causes selection of drug resistant leukaemia cells that will expand when the growth factor supply recovers.
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Multi-drug resistance is one of the most serious problems in the
treatment of malignant tumours. Although studies have revealed
its complicated mechanisms including enhancement in drug export
by ATP-binding cassette transporter proteins (reviewed by Ross,
2000), activated drug detoxiﬁcation by glutathione S-transferase
(reviewed by Zhang et al, 1998), reduction in cell death commit-
ment by loss or mutation of p53 (Aas et al, 1996 and Ju et al,
1998), topoisomerase II down-regulation (Shen et al, 1989; Yun
et al, 1995) and apoptosis inhibition by over-expression of Bcl-2
family proteins (reviewed by Reed, 1997), triggering events that
induce multi-drug resistance are not completely understood. It
has been shown that the hypo-nutritive conditions promote a tran-
sient multi-drug resistance in solid tumours. The local hypo-
glycaemia or hypoxia induces multi-drug resistance although nutri-
tive improvement instantaneously rescues the drug resistance
(Hughes et al, 1989; Lee, 1992; Shen et al, 1987; Tomida et al,
1996). Indeed, hypo-nutritive conditions occur in vivo in solid
tumours with an enlargement of tumour size and subsequent blood
supply loss (Hockel et al, 1996). By contrast, leukaemic cells are
seldom put under such conditions because they grow in a dissemi-
nate manner in blood ﬂow or bone marrow, where nutrients are
abundant, and also leukaemia demonstrates neoangiogenesis. On
the other hand, growth-factor-deﬁcient conditions may occur to
leukaemic cells in vivo when stromal functions are severely
damaged after intensive chemotherapy or bone marrow occupation
by malignant cells (Ben-Ishay et al, 1990).
In the present study, we studied the effects of a transient growth
factor deﬁciency on drug sensitivities using Granulocyte-macro-
phage colony-stimulating factor (GM-CSF)-dependent human
leukaemic MO7e line, which was established from magakaryocytic
leukaemia patient as the cells whose growth completely depends on
GM-CSF or interleukin-3 (Avanzi et al, 1990). We show that a
recurrent growth factor starvation results in a permanent reduction
in drug sensitivity. The molecular mechanism and the clinical rele-
vance of this phenomenon will be discussed.
MATERIALS AND METHODS
Cells, the cytokine and drugs
Human leukaemic MO7e cells were maintained in RPMI1640 (Life
Technologies, Inc., Grand Island, NY, USA) supplemented with
10% heat inactivated foetal calf serum (FCS) and also 10 ng ml
71
of recombinant human GM-CSF, which was provided by Kirin
Brewery Company, Ltd. (Tokyo, Japan). Human leukaemic K052
cells were provided by Health Science Research Resources Bank
(Osaka, Japan) and maintained in a-MEM (Life Technologies,
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sInc., Grand Island, NY, USA) supplemented with 10% heat inacti-
vated foetal calf serum. Doxorubicin, etoposide and actinomycin D
were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
In short drug exposure experiments, relatively high doses of drugs
were used. The 5 mgm l
71 of etoposide or 1 mgm l
71 of doxyrubi-
cin, both of which are used clinically (Aydiner et al, 2000, Battista
et al, 1991), and 1 mgm l
71 of actinomycin D, which is commonly
used in in vitro apoptosis-inducing experiments (Cotter et al,
1992), were added to the cells, and the cell viability was tested after
incubation for 6 h or 14 h.
Preparation of the growth factor withdrawal-resistant
MO7e sublines
The ﬂow chart of the procedure (Figure 1). First, MO7e were
seeded in a 96-multiwell plate with aliquot volume of 100 mla t
the density of 1610
5 ml
71 in the absence of GM-CSF and then
cultured at 378C for 2 weeks. Compatible to the previous report
that the growth of MO7e completely depends on GM-CSF (Avanzi
et al, 1990), the majority of MO7e died within 4 days after GM-CSF
deprivation and we could hardly detect the viable cells by direct
microscopic observation at day 14. Then we added GM-CSF to each
well to expand the viable cells if they existed. After 1 week’s expan-
sion, we found that several wells contained viable cells. These cells
were cultured again in the absence of GM-CSF as the 2nd selection.
After 2 weeks of incubation, GM-CSF was added again to expand
viable cells. This procedure was repeated three times. After the ﬁnal
expansion, we found that 12 out of 96 wells contained viable cells.
As these cells formed multi-focus in the wells, we performed the
clonal isolation by limiting dilution in a 96-multiwell plate picking
up cells from the well that contained the largest number of viable
cells. After seeding of the cells, the three cycles of GM-CSF with-
drawal/re-addition procedure were performed as before. After the
ﬁnal expansion, eight clones were obtained. These sublines were
maintained in the presence of GM-CSF as well as parental cells.
Reverse transcription–polymerase chain reaction
(RT–PCR)
Messenger RNA was extracted from 8610
7 cells by Fast Track 2.0
Kit (Invitrogen Co. Carsland, CA, USA) and suspended in 50 mlo f
0.1% diethyl pyrocarbonate-containing water. The 1 ml of mRNA
solution was used for reverse transcriptase reaction with AMV
reverse transcriptase XL (Takara Shuzo Co., Ltd. Shiga, Japan)
and the product was suspended in 20 ml of DEPC water. PCR
was carried out by Bio Medical Laboratories Co. Ltd. (Tokyo,
Japan) using DNA Thermal Cycler PJ2000 (The Perkin-Elmer
Co. Foster City, CA, USA) with 16 pmol ml
71 of MDR1 sense
primer (5'-AAGCTTAGTACCAAAGAGGCTCTG-3'), 16 pmol
ml
71 of MDR1 antisense primer (5'-GGCTAGAAACAATAGT-
GAAAACAA-3'), 4 pmol ml
71 of b2-microglobulin sense primer
(5'-GTGGAGCATTCAGACTTGTC-3') and 4 pmol ml
71 of b2-
microglobulin antisense primer (5'-CTGCTTACATGTCTC-
GATCC-3') The PCR program was 948C; 30 s, 558C; 1 min,
728C; 1 min for 30 cycles. The product was separated by agarose
gel electrophoresis and the DNA (the product sizes: MDR1;
243 bp, b2-microglobulin; 160 bp) was visualized by ethidium
bromide. For molecular marker, smart ladder (0.2 k–10 kbp)
(WAKO Pure Chemical Industries, Osaka, Japan).
Evaluation of apoptosis
DNA fragmentation assay was performed by extracting the low
molecular weight DNA and visualizing the internucleosomal
DNA breakdown as previously described (Saeki et al, 1997). The
magnitude of apoptosis was quantiﬁed by calculating percentage
of hypodiploid cell population in DNA content analysis by using
ﬂuorescence-activated cell sorter (FACS) as described previously
(Okuma et al, 2000). Morphological study was performed by direct
microscopic observation with phase contrast examination (Olym-
pus Optical Co. Ltd., Tokyo, Japan).
Assessment of clonogenisity
Cells were seeded at the density of 1610
2 ml
71 in 24-well multi-
well dish and cultured in CO2 gas incubator. After 2 weeks,
numbers of the colonies that consist of more than 50 cells were
counted.
Determination of 50% inhibitory concentrations (IC50) and
90% inhibitory concentrations (IC90) by 3 days WST assay
Cells were cultured at 3610
5 ml
71 in 24-multiwell dish in the
presence of GM-CSF and various doses of drugs (1, 2, 4, 8, 10,
20, 40, 80 ng ml
71 of doxorubicin; 2.5, 5, 10, 20, 40 ng ml
71 of
etoposide; 5, 10, 20, 40, 80 pg ml
71 of actinomycin D). After
72 h, the viability of the cells was assessed by 2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazo-
lium (WST)-8-reducing activity using Cell Counting Kit-8 (WAKO
Pure Chemical Industries) according to the manufacturer’s proto-
col. Brieﬂy, aliquot volume of the cells were translocated into 96-
multiwell dish and incubated with WST solution. After 2 h, the
absorbance at 490 nm (A490) and at 595 nm (A595) was exam-
ined. Then the percentages of DA values (A490–A595) of the
drug-treated cells to those of non-treated cells were calculated.
These values were plotted on the 2-dimensioned graph with hori-
zontal axis for drug doses and vertical axis for relative DA values.
The IC50 and IC90 were determined as the dose that gave the 50
and 90% DA value, respectively. The results from independent
triplicate experiments were used for the determination of IC50.
Immunostaining of p-glycoprotein
Immunostaining of p-glycoprotein was performed as described
previously (Saeki et al, 2000) using cells ﬁxed on slide glasses
by cytospin apparatus (Cytospin2, SHANDON, Pittsburgh, PA,
USA), which were further ﬁxed with acetone:methanol solution
(1:3). The ﬁxed cells were incubated with 50 ml of PBS contain-
ing anti-p-glycoprotein monoclonal antibody (1:100 dilution)
(DAKO A/S, Denmark) and FCS (1:200 dilution) at 378C for
60 min, washed with 10 ml of PBS for 5 min by three times
and further incubated with 50 ml of PBS containing FITC-conju-
gated gout anti-mouse IgG (1:50 dilution) (CHEMICON
International, Inc., Temecula, CA, USA) and FCS (1:100 dilution)
at 378C for 60 min. After washing them with PBS by ﬁve times,
cells were observed under ﬂuorescent microscopy (Olympus Opti-
cal Co. Ltd., Tokyo, Japan). The stained cells also observed by
light microscopy with Normarsky differentiated interference
contrast (Olympus). For a positive control, human leukaemic
K052 cells (Health Science Research Resources Bank, Osaka,
Japan) were used.
GM-CSF stimulation and Western blotting
After 20 h incubation in the absence of GM-CSF, MO7e cells
stimulated with GM-CSF (10 ng ml
71). After 5 min incubation
at 378C, cells were collected, lysed by 16 Laemmli’s sample buffer
and boiled. Aliquot (i.e. 5610
4 cells) was used for Western blot-
ting. First antibody reaction was performed using anti-
phosphorylation-speciﬁc Stat 5 monoclonal antibody (New
England Biolabs, Inc., Beverly, MA, USA), phosphorylation-speciﬁc
Akt polyclonal antibody (New England Biolabs, Inc.) and phos-
phorylation-speciﬁc monoclonal extracellular signal-regulated
kinase (ERK) antibody (New England Biolabs, Inc.). Anti-bcl-2
monoclonal antibody (Pharmingen, San Diego, CA, USA), anti-
HSP70 monoclonal antibody (Santa Cruz Biotechnology Inc., Santa
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sCruz, CA, USA), anti-p53 monoclonal antibody (Santa Cruz
Biotechnology Inc.) and anti-p21 monoclonal antibody (Pharmin-
gen, San Diego, CA, USA) and anti-topoisomerase II a polyclonal
antibody (Santa Cruz Biotechnology Inc.) were also used in other
experiments. Second antibody reaction and the ﬁnal detection
procedure were performed as previously described (Saeki et al,
1997).
Examination of the surface expression of CD61 by
ﬂuorescence-activated cell sorting (FACS)
The 5610
5 cells were collected, washed twice by PBS containing
10% foetal calf serum and then incubated with 10 ml of FITC-
conjugated anti CD61 antibody (DAKO A/S, Denmark) or 10 ml
of control FITC-conjugated mouse IgG1 (Beckton Dickinson,
Mountain View, CA, USA) at 48C for 30 min. Then, cells were
washed with 10% foetal calf serum-containing PBS for four times,
and the CD61 expression was analyzed by FACScalibur (Beckton
Dickinson).
Karyotype analysis
Karyotype analysis was performed by Bio Medical Laboratories Co.
Ltd. (Tokyo, Japan) by the conventional method (Benn and Perle,
1992). Chromosomes were stained with Giemsa solution and
examined by a microscope. Twenty metaphase spreads were exam-
ined in each sample.
Fluorescence in situ hybridization (FISH) analysis
Cells were ﬁxed, denatured, hybridized with speciﬁc chromosomal
probes (WCP 17 SpectrumOrange and WCP 22 SpectrumGreen)
according to the manufacturer’s protocol (Vysis, Inc., IL, USA)
and photographed through ﬂuorescent microscopy by Bio Medical
Laboratories Co. Ltd. (Tokyo, Japan).
RESULTS
Acquisition of growth-factor-withdrawal-resistant clones
To know whether malnutritive conditions, including growth
factor deﬁciency, would possibly promote drug resistance in
leukaemia, we tried to select clones that had adapted to growth
factor deprivation using GM-CSF-dependent human megakaryo-
cytic leukaemic MO7e cells as described in Materials and
methods. We could actually obtain eight clones after the ﬁnal
selection. We randomly selected three clones (cl-1, cl-2, and
cl-3) and maintained them in the presence of GM-CSF. Chro-
mosomal analysis conﬁrmed that they were derivatives of
MO7e and not the contamination of other cell lines (Table
1). Using these three clones, we determined the resistance to
GM-CSF withdrawal. All these clones survived a signiﬁcantly
longer time than the parental cells in the absence of GM-CSF
(Figure 2A). They underwent G1 arrest at day 4 after GM-
CSF starvation (Figure 2B), while parental cells underwent
apoptosis as early as day 1 as determined by DNA fragmenta-
tion assay (Figure 2C). To exclude the possibility that an
enhanced survival in the absence of GM-CSF comes from a
ligand-independent activation of GM-CSF receptor, activities of
its downstream target molecules were examined. As shown in
Figure 2D, the phosphorylation of transducer and activator of
transcription 5 (Stat 5), Akt and extracellular signal-regulated
kinase (ERK) were all regulated in a GM-CSF-dependent
manner, indicating that GM-CSF withdrawal resistance was
not due to the ligand-independent activation of GM-CSF recep-
tor.
Thus, the growth factor withdrawal-resistant MO7e clones were
obtained after repetitive growth factor starvation.
Growth-factor-withdrawal-resistant clones showed drug
resistance
We next compared the sensitivities to chemical drugs in the
presence of GM-CSF among parental cells and the growth-
factor-withdrawal-resistant clones. Because cell cycling speed often
affects the drug sensitivities, we checked the growth rate of paren-
tal cells and sublines in the presence of GM-CSF. When cells were
seeded at a relatively high density of 3610
5 ml
71, growth speed
of the sublines was not at all slower, or even faster, than that of
the parental line (Figure 3A). On the other hand, the growth rate
of sublines decreased when seeded at a relatively low density of
7610
4 ml
71 (Figure 3B). Moreover, the growth of sublines
remarkably reduced and, as a result, the clonogenic activity
became considerably lower when seeded at a lowest density of
1610
2 ml
71 (Figure 3C). For this reason, the following experi-
ments were performed at the density of 3610
5 ml
71, where
growth rate of parental cells and sublines did not signiﬁcantly
differ.
First we performed a short-term WST assay using relatively
high doses of drugs (i.e. 5 mgm l
71 of etoposide, 1 mgm l
71 of
doxorubicin or 1 mgm l
71 of actinomycin D). The cell viability
was examined after an incubation for 6 h or 14 h by WST asssay.
We found that sublines showed higher viability than parental cells
at any time point (Figure 4A,B and C). To check the cell death
commitment time in each clone, drugs were transiently added.
Practically, cells were exposed to 2.5 mgm l
71 of etoposide for
30 min, 0.5 mgm l
71 of doxorubicin for 30 min or 1 mgm l
71
of actinomycin D for 6 h, cell growth was chased after washing
out the drugs. We found that the growth of the sublines recov-
ered while parental cells did not grow but died (Figure 4D,E
and F). To evaluate the magnitude of drug resistance, the 3 days
WST assay was performed and IC50 value was determined. Etopo-
side, doxorubicin or actinomycin D was added to the cells at
indicated doses with dilution factor of 2, and the relative WST-
reducing activities of drug-treated samples to those of non-treated
ones were assessed at day 3. As shown in Figure 5A, viability
curves of sublines for etoposide were apparently shifted to the
right, and IC50 values were increased by 4–7-fold (Table 2).
Although no signiﬁcant change in IC50 values for doxorubicin
was detected (Table 2), we found slopes in the viability curves
of the sublines at higher doses (Figure 5B). Actually, IC90 values
were increased by 2–6-fold in the sublines (Table 2). For actino-
mycin D, there was no increment in either IC50 or IC90 values
(Figure 5C).
Plating of MO7e cells in a 96 multi-well dish at the
density of 1´10
5/ml in GM-CSF-depleted medium
Incubation at 37° C for 2 weeks in the absence of GM-
CSF to select GM-CSF withdrawal-resistant cells.
Incubation at 37° C for 1 week in the presence of GM-
CSF to expand the viable cells.
Cell cloning by limiting dilution picking up cells from
one of the wells in 96 multi-well dish.
Incubation at 37° C for 2 weeks in the absence of GM-
CSF to select GM-CSF withdrawal-resistant cells.
Incubation at 37° C for 1 week in the presence of GM-
CSF to expand the viable cells.
Expansion of viable cells in a large scale in the presence of GM-CSF
*
repeated by 3 times
*
repeated by 3 times
Figure 1 The ﬂow diagram of the GM-CSF withdrawal-resistant cell
cloning procedure.
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Figure 2 MO7e sublines with elongated life spans in the absence of GM-CSF but with normal intracellular signalling after GM-CSF receptor. (A)–(C)
Parental MO7e cells and the three sublines (cl-1, cl-2 and cl-3) were cultured in the absence of GM-CSF at the density of 3610
5 ml
71 in a 24 multi-well
plate. (A) Viable cell number was counted in time course. (B) DNA content analysis was performed at day 4 (a; parental cells, b; cl-1, c; cl-2, d; cl-3). (C)
DNA fragmentation assay was performed at day 1 (M indicates the molecular marker. Lane 1; parental cells cultured with GM-CSF, lane 2; parental cells
cultured without GM-CSF, lane 3; cl-1, lane 4; cl-2, lane 5; cl-3 cultured without GM-CSF. (D) After 20 h starvation of GM-CSF, parental cells and the sub-
lines were stimulated by water (indicated as 7)o rb y1 0n gm l
71 of GM-CSF (indicated as +) for 5 min. Lysate was prepared from aliquot number of cells
and Western blotting was performed using anti-phosphorylated Stat-5 (Tyr 694) antibody (upper), anti-phosphorylated Akt (Ser 473) antibody (middle) and
anti-phosphorylated ERK (Thr 202/Tyr 204) antibody (lower).
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Figure 4 A short-term WST assay and a transient drug exposure assay. (A)–(C) Parental cells and sublines were cultured at the density of 3610
5 ml
71
in the presence of etoposide (5 mgm l
71)( A), doxorubicin (1 mgm l
71)( B) or actinomycin-D (1 mgm l
71)( C), and WST assay was performed as indi-
cated time points. Horizontal axis indicates the percentages of WST-reducing activities of drug-treated samples to those of drug-untreated one in each cell
line. (D)–(E) The 3610
5 ml
71 of parental cells and the sublines were transiently treated with etoposide (2.5 mgm l
71) for 30 min (D), doxorubicin
(0.5 mgm l
71) for 30 min (E) or actinomycin D (1 mgm l
71) for 6 h (F), and then cells were washed. After 24 h incubation, cells were diluted. After in-
cubation for indicated time, the number of total viable cells was counted. Results of the three independent experiments were shown. (&: parental cells,^:
cl-1, *: cl-2, D: cl-3).
C
e
l
l
 
n
u
m
b
e
r
 
(
´
1
0
5
m
l
–
1
)
30
20
10
0
A
C
e
l
l
 
n
u
m
b
e
r
 
(
´
1
0
5
m
l
–
1
)
30
15
10
5
0
C
l
o
n
o
g
e
n
i
c
 
s
u
r
v
i
v
a
l
 
(
%
)
70
60
50
40
30
20
10
0
0 1 2 3 (days) 0 1 2 3 (days) P cl-1 cl-2 cl-3
B C
parental
cl-1
cl-2
cl-3
parental
cl-1
cl-2
cl-3
n=3 n=3 n=3
Figure 3 The growth rate of MO7e sublines depends on their cell density. Parental cells (&) and sublines (cl-1; ^, cl-2; open circle, cl-3; D) were cultured
in the presence of GM-CSF at the density of 3610
5 ml
71 (A), 7610
4 ml
71 (B) and 1610
2 ml
71 (C) in 24 multi-well dish. Viable cell number was
counted in time course (A and B) or number of the colonies was counted at day 14 (C). Results of three independent experiments were shown.
Growth factor deprivation promotes drug resistance
K Saeki et al
296
British Journal of Cancer (2002) 86(2), 292–300 ã 2002 The Cancer Research Campaign
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sTable 1 Karyotype analysis
Parental 46, X, t (X;1) (p11.2; p34), add(4) (p31)
cl-1 46, X, t (X;1) (p11.2; p34), add(4) (p31) add (22) (p11.2)
cl-2 46, X, t (X;1) (p11.2; p34), add(4) (p31) add (22) (p11.2)
cl-3 46, X, t (X;1) (p11.2; p34), add(4) (p31) add (22) (p11.2)
A
M 12345
K052 Parental cl-1
B
Hsp70
Bcl-2
Bcl-xL
Bax
p53
p21
topo II
parental
cl-2
cl-1 cl-3
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0
Figure 6 The expressions of drug resistance-related genes and the differentiation marker. (A) The mRNA was extracted from mdr1-positive K052 cells
(lane 1), parental cells (lane 2), cl-1 (lane 3), cl-2 (lane 4) and cl-3 (lane 5), and the expression of mdr1 message (upper) or b2 microglobulin (lower) was
examined by RT–PCR. M indicates the DNA molecular marker. (B) The mdr1-positive K052 (left) parental cells (middle) cl-1 (right) were ﬁxed, and p-
glycoprotein expression was examined by immunostaining (upper). Lower panels indicate the photographs by light microscopy with Normarsky differen-
tiated interference contrast. (C) Lysate of equivalent numbers of parental cells and the sublines were prepared and Western blotting was performed using
antibodies against Hsp70, Bcl-2, Bcl-xL, Bax, p53, p21 and topoisomerase IIa.( D) The surface expression of CD61 was examined by FACS. The thin lines
indicate the staining with control FITC-conjugated mouse IgG and the bold lines indicate the staining with anti-CD61 antibody.
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Figure 5 The 3 days WST assay for the determination of IC50 and IC90. The 3610
5 ml
71 of parental cells (&) and sublines (cl-1; ^, cl-2; *, cl-3; D)
were treated with etoposide (A), doxorubicin (B) and actinomycin D at indicated doses, and WST assay was performed at day 3. Horizontal axis indicates
the percentages of WST-reducing activities of drug-treated samples to the untreated ones in each line. The results from the three independent experiments
were shown.
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term resistant to etoposide, doxorubicin and actinomycin D with
delays in cell death commitment time and the long-term resistant
to etoposide and doxorubicin.
Expressions of drug-resistance-associated genes and a
differentiation marker
To understand the molecular mechanism of drug resistance in the
clones, expressions of drug resistance-related genes were examined.
The expression of mdr1, an important gene for drug export, was
examined, but it was neither detected in sublines nor parental cells
by RT–PCR (Figure 6A) or immunocytochemistry (Figure 6B).
Then we tested the expression of hsp 70, a regulator of heat shock
and chemical drug. The protein expression of Hsp 70 did not differ
among parental cells and sublines (Figure 6C). We also checked the
expression of bcl-2 family proteins, regulators of drug-induced
apoptosis, and found a mild up-regulation in cl-1 and remarkable
up-regulation in cl-2 and cl-3 in Bcl-2 protein expression without a
signiﬁcant alteration in other bcl-2 family protein expressions
(Figure 6C). We also examined the expression of p53, which
reportedly renders cells drug-sensitive (Aas et al, 1996 and Ju et
al, 1998), and a complicated result was obtained; cl-1 with a simi-
lar p53 expression as in parental cells; cl-2 with a signiﬁcantly up-
regulated p53 expression; cl-3 with almost loss of p53 expression
(Figure 6C). To know the activity of p53, we examined the expres-
sion levels of p21, a downstream target of p53. We found that the
protein expression level of p21 precisely paralleled with that of p53
(Figure 6C), suggesting that p53 had wild type transcriptional
activity in each line although p53 expression did not show correla-
tion with drug resistance. Moreover, we could not detect signiﬁcant
differences in topoisomerase II a expression among parental and
sublines (Figure 6C). We further checked the differentiation states
of parental cells and sublines because drug sensitivity can report-
Figure 7 FISH analysis. One of the GM-CSF withdrawal-resistant subline (cl-1) was ﬁxed on the slide glass, and FISH analysis using probes for chromo-
some 17 and chromosome 22 was performed.
Table 2 Drug sensitivity of parental cells and the sublines
Etoposide
Doxorubicin
Actinomycin D
IC50 (units: ng ml
71)I C 50 IC90 (units: ng ml
71)I C 50 (units: pg ml
71)
Parental 5.3+1.4 7.3+0.7 8.5+0.02 52.8+0.2
cl-1 38.0+2.5 14.0+0.6 49.7+0.5 64.5+3.9
cl-2 24.0+0.3 10.3+0.8 18.0+6.5 60.2+2.7
cl-3 38.0+2.5 14.4+1.5 27.0+0.8 63.5+1.2
The 3610
5 ml
71 of parental and the sublines (cl-1, cl-2 and cl-3) were treated with etoposide, doxo-
rubicin and actinomycin D at indicated doses in Figure 5. The relative WST activities were assessed at
day 3. After plotting the data on semi-logarithmic graphs (Figure 5), IC50 and IC90 values were deter-
mined. The independent three (for eptoposide and doxorubicin) or two (for actinomycin D)
experiments were performed.
Growth factor deprivation promotes drug resistance
K Saeki et al
298
British Journal of Cancer (2002) 86(2), 292–300 ã 2002 The Cancer Research Campaign
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sedly be affected by differentiation (Costello et al, 2000; Ohashi et
al, 2000). The surface expression of megakaryocytic differentiation
marker of CD61 was examined, and we found a slight decrement in
CD61 expression in sublines in reciprocal proportion to the Bcl-2
expression level (Figure 6D).
Thus, an up-regulation of Bcl-2 protein expression and a slight
down-regulation of CD61 was a common feature detected in GM-
CSF-withdrawal-resistant clones.
FISH analysis
We ﬁnally performed FISH analysis to understand the chromoso-
mal translocation of add (22) (p11.2) using one of the clones. As
shown in Figure 7, the translocation turned to be der (22) t (17;
22) (q21; p11.2).
DISCUSSION
We showed that recurrent growth factor starvation promotes the
emergence of drug resistant clones in leukaemic cells.
Malnutritive conditions such as anoxia or aglycaemia reportedly
promote multi-drug resistance in solid tumours by inducing
glucose-regulated set of stress proteins (Hughes et al, 1989; Lee,
1992; Shen et al, 1987; Tomida et al, 1996) or by proteolytically
depleting topoisomerase II, a target of etoposide (Shen et al,
1989; Yun et al, 1995). In these cases, drug resistance persists only
in a transient manner, and an improvement in nutritive conditions
immediately restores the drug sensitivity. In our case, however, the
drug resistance persists even in the presence of GM-CSF. Moreover,
we could not detect signiﬁcant difference in topoisomerase II a
(Figure 6C) and topoisomerase II b (data not shown). Thus,
distinct mechanisms are working in the GM-CSF withdrawal-resis-
tant clones. We could not obtain any evidence for activated drug
export system because the expression of Mdr1 (Figure 6C) nor
MRP1 (data not shown) was not detected in either clone. With
regard to p53, we did not observe any correlation between its
expression and drug resistance: no changes of p53 in cl-1, up-regu-
lation in cl-2 and reduction in cl-3. Thus, p53 may not be involved
in drug resistance in our case. On the other hand, Bcl-2 up-regula-
tion can be a good candidate for the cause of drug resistance. Bcl-2
over-expression is reportedly associated with therapeutic resistance
and poor outcome in leukaemic cases in clinical ﬁelds (Karakas et
al, 1998). As we showed, Bcl-2 expression was indeed up-regulated
in all subclones although there was a difference in the magnitude of
up-regulation among the clones; about two-fold up-regulation in
cl-1 and four-fold in cl-2 and cl-3 (data not shown). Because even
a slight Bcl-2 up-regulation can render cells resistant to apoptosis
(Shimura et al, 2000), it seems quite possible that a relative weak
Bcl-2 up-regulation in cl-1 promoted drug resistance. A recent
report, however, showed that bcl-2 over-expression did not rescue
the reproductive cell death following drug treatments in vitro
(Tannock and Lee, 2001). As we showed, the higher the Bcl-2
expression level is, the lower the clonogenic activity (Figure 3C).
We speculate that a high expression of Bcl-2 per se might be some-
what toxic for clonogenic survival, and thus bcl-2 over-expression
failed to rescue drug-induced reproductive cell death in vitro. Why
is bcl-2 up-regulation clinically associated with therapeutic resis-
tance? We propose a ‘two hits theory’ in bcl-2-associated
therapeutic resistance that a certain second hit has compensated
the bcl-2-induced clonogenic reduction. It may be of interest to
search the gene that rescues the clonogenic activity in bcl-2-over-
expressing cells.
It is known that chromosomal abnormalities are often found in
drug-resistant leukaemic cells. Our MO7e sublines had a common
chromosomal abnormality of add (22) (p11.2). FISH analysis of cl-
1 showed that this rearrangement was der (22) t (17; 22) (q21;
11.2) (Figure 7). At 17q21 is located the retinoic acid receptor
a(RARa) gene, whose rearrangement contributes to the develop-
ment of acute promyelocytic leukaemia. Hybridization analysis,
however, revealed that RARa gene was not located at the re-
arranged locus (K Saeki, unpublished observation), so other genes
are responsible for the drug resistance if chromosomal transloca-
tion could be involved in it.
What events trigger the acquisition of drug resistance in vivo?
Environmental stresses such as chemical drugs and X-ray irradia-
tion are reported to induce multi-drug resistance (Licht et al,
1991). Our results further propose that the starvation of growth
factor can be a trigger for it. After an intensive chemotherapy or
even during the natural course of leukaemia progression, local
growth factor concentration in bone marrow can be low as a result
of stromal dysfunction. Under these conditions, growth factor
withdrawal-resistant clones might be selected, which can expand
after stromal recovery. Although growth factors can be produced
outside the bone marrow, their supply must be too short to
support the haematopoietic cell growth in the bone marrow
because only an extramedullary haematopoiesis can be observed
in cases of severe stromal damage such as myeloﬁbrosis. We
suggest that chemotherapeutic protocols with least stromal toxicity
can possibly prevent the emergence of multi-drug resistant leukae-
mic cells.
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